Madrigal Pharmaceuticals Inc (MDGL)
329.50
-1.82
(-0.55%)
USD |
NASDAQ |
Nov 05, 09:42
Madrigal Pharmaceuticals Profit Margin (Quarterly): -172.0% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -172.0% |
| June 30, 2024 | -1.04K% |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 |
| Date | Value |
|---|---|
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-1.04K%
Minimum
Jun 2024
-172.0%
Maximum
Sep 2024
-605.1%
Average
-605.1%
Median
Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 13.80% |
| Sarepta Therapeutics Inc | 1.78% |
| ADMA Biologics Inc | 29.91% |
| Intra-Cellular Therapies Inc | -15.03% |
| Entrada Therapeutics Inc | 58.11% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -89.04% |
| Return on Assets | -62.73% |
| Return on Invested Capital | -74.25% |
| Gross Profit Margin (Quarterly) | 96.54% |
| Operating Margin (Quarterly) | -187.1% |
| Return on Net Operating Assets | -2.12K% |